Core Viewpoint - VolitionRx Limited has announced a public offering of 11,550,000 shares of common stock and warrants, aiming to raise approximately $6.0 million in gross proceeds before expenses [1][3]. Offering Details - The public offering price is set at $0.52 per share, with each warrant priced at $0.01, and an exercise price of $0.60 per share [1]. - The underwriter has a 30-day option to purchase an additional 1,732,500 shares and warrants to cover overallotments [2]. - If the warrants are fully exercised, the additional gross proceeds could reach approximately $6.9 million [3]. Use of Proceeds - The net proceeds from the offering will be utilized for research, product development, clinical studies, commercialization, working capital, and potential strategic acquisitions [4]. Company Overview - Volition is a multinational company focused on advancing epigenetics, aiming to improve early detection and monitoring of diseases [8]. - The company is developing cost-effective blood tests for various diseases, including certain cancers and conditions associated with NETosis [9]. - Research and development activities are primarily based in Belgium, with additional offices in the U.S. and London [10].

Core Viewpoint - VolitionRx Limited will host a conference call on August 15, 2025, to discuss its Q2 2025 financial and operational results, along with a business update [1][2]. Group 1: Conference Call Details - The conference call is scheduled for August 15, 2025, at 8:30 a.m. U.S. Eastern Time [2]. - Key executives participating in the call include Louise Batchelor (Group Chief Marketing & Communications Officer), Cameron Reynolds (President and Group CEO), Terig Hughes (Group CFO), and Dr. Andrew Retter (Chief Medical Officer) [2]. - A live audio webcast will be available, and a telephone replay will be accessible until August 29, 2025 [3]. Group 2: Company Overview - Volition is a multinational company focused on advancing epigenetics to improve outcomes for individuals and animals with serious diseases through early detection and monitoring [4]. - The company is developing cost-effective blood tests for detecting and monitoring various diseases, including certain cancers and conditions related to NETosis, such as sepsis [5]. - Research and development activities are primarily based in Belgium, with additional facilities in the U.S. and London [5].

Core Viewpoint - VolitionRx Limited has announced definitive agreements for the purchase and sale of common stock, aiming to raise approximately $1.21 million in gross proceeds, with potential additional proceeds of about $1.3 million from warrants if fully exercised [1][3]. Group 1: Stock Offering Details - The company will sell 156,250 shares of common stock to insiders at $0.64 per share, and 1,734,375 shares along with warrants to other existing stockholders at the same price [1][2]. - Each warrant has an exercise price of $0.768, is immediately exercisable, and expires five years from the issuance date [1][2]. Group 2: Financial Implications - The total gross proceeds from the offering are expected to be $1.21 million before expenses, with an additional potential of $1.3 million from the exercise of warrants [3]. - The net proceeds will be utilized for research, product development, clinical studies, commercialization, working capital, and potential strategic acquisitions [3]. Group 3: Regulatory Information - The offering is conducted under a shelf registration statement filed with the SEC, and the related prospectus will be available on the SEC's website [4]. Group 4: Company Overview - VolitionRx is a multinational company focused on advancing epigenetics, aiming to improve early detection and monitoring of diseases, including cancers and conditions related to NETosis [6][7]. - The company's research and development activities are primarily based in Belgium, with additional offices in the U.S. and London [8].

Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, disease and treatment monitoring. Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detec ...